Yining Wang,Lijing Zhu,Lian Xu,Liang Dong,Haitao Zhao,Lianghua Li,Gang Huang,Ruohua Chen,Jianjun Liu
{"title":"长轴位68Ga-PSMA-11 PET比短轴位PET在前列腺癌诊断中的优势:一项头对头的比较","authors":"Yining Wang,Lijing Zhu,Lian Xu,Liang Dong,Haitao Zhao,Lianghua Li,Gang Huang,Ruohua Chen,Jianjun Liu","doi":"10.1007/s00259-025-07546-y","DOIUrl":null,"url":null,"abstract":"BACKGROUND AND PURPOSE\r\nPrevious studies have shown that long axial field-of-view (LAFOV) 68Ga-PSMA-11 PET/CT can significantly improve the detection rate compared to short axial field-of-view (SAFOV) 68Ga-PSMA-11 PET/CT in prostate cancer. However, the diagnostic efficiency between the two scans was compared in different cohorts, not directly within the same patients. Whether LAFOV 68Ga-PSMA-11 PET could improve image quality, enhance lesion quantification, and impact patient treatment decisions in the same patients remains unclear. To address this research gap, we performed a direct comparison of LAFOV and SAFOV 68Ga-PSMA-11 PET in the same cohort of prostate cancer patients to evaluate whether LAFOV 68Ga-PSMA-11 PET could enhance lesion identification and modify clinical management compared to SAFOV 68Ga-PSMA-11 PET.\r\n\r\nMETHODS\r\nThirty-four patients with prostate cancer undergoing routine 68Ga-PSMA-11 PET/CT were included and underwent a same-day dual-scanning protocol. Half of the patients first underwent a clinically routine SAFOV PET scan using continuous bed motion, followed immediately by LAFOV PET (5-minute acquisition in list mode); the other half underwent scanning in the reverse order. The image quality of LAFOV and SAFOV 68Ga-PSMA-11 PET was compared using subjective scoring and objective parameters. Objective parameters, including maximum and mean standardized uptake values (SUVmax and SUVmean), signal-to-noise ratio (SNR), and tumor-to-background ratio (TBR), were measured and compared.\r\n\r\nRESULTS\r\nLAFOV 68Ga-PSMA-11 PET exhibited superior image quality compared to SAFOV PET based on both subjective and objective parameters. LAFOV 68Ga-PSMA-11 PET had better image quality and higher lesion SUVmax, SNR, and TBR compared to SAFOV PET. In 17.65% of patients, LAFOV 68Ga-PSMA-11 PET detected additional lesions that were unidentified on SAFOV 68Ga-PSMA-11 PET. Compared to SAFOV 68Ga-PSMA-11 PET, LAFOV 68Ga-PSMA-11 PET detected additional lesions in 33.33% of patients with biochemical recurrence and 9.09% of patients with newly diagnosed prostate cancer, leading to significant changes in clinical management.\r\n\r\nCONCLUSIONS\r\nIn this head-to-head comparison, LAFOV 68Ga-PSMA-11 PET demonstrated superior image quality, enhanced lesion detection, and a significant impact on clinical management for both biochemical recurrence and newly diagnosed prostate cancer patients compared to SAFOV 68Ga-PSMA-11 PET. These findings suggest that LAFOV 68Ga-PSMA-11 PET may be the preferred imaging modality for comprehensive prostate cancer evaluation.","PeriodicalId":11909,"journal":{"name":"European Journal of Nuclear Medicine and Molecular Imaging","volume":"88 1","pages":""},"PeriodicalIF":7.6000,"publicationDate":"2025-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Superiority of long axial field-of-view 68Ga-PSMA-11 PET over short axial field-of-view PET in prostate cancer: a head-to-head comparison.\",\"authors\":\"Yining Wang,Lijing Zhu,Lian Xu,Liang Dong,Haitao Zhao,Lianghua Li,Gang Huang,Ruohua Chen,Jianjun Liu\",\"doi\":\"10.1007/s00259-025-07546-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"BACKGROUND AND PURPOSE\\r\\nPrevious studies have shown that long axial field-of-view (LAFOV) 68Ga-PSMA-11 PET/CT can significantly improve the detection rate compared to short axial field-of-view (SAFOV) 68Ga-PSMA-11 PET/CT in prostate cancer. However, the diagnostic efficiency between the two scans was compared in different cohorts, not directly within the same patients. Whether LAFOV 68Ga-PSMA-11 PET could improve image quality, enhance lesion quantification, and impact patient treatment decisions in the same patients remains unclear. To address this research gap, we performed a direct comparison of LAFOV and SAFOV 68Ga-PSMA-11 PET in the same cohort of prostate cancer patients to evaluate whether LAFOV 68Ga-PSMA-11 PET could enhance lesion identification and modify clinical management compared to SAFOV 68Ga-PSMA-11 PET.\\r\\n\\r\\nMETHODS\\r\\nThirty-four patients with prostate cancer undergoing routine 68Ga-PSMA-11 PET/CT were included and underwent a same-day dual-scanning protocol. Half of the patients first underwent a clinically routine SAFOV PET scan using continuous bed motion, followed immediately by LAFOV PET (5-minute acquisition in list mode); the other half underwent scanning in the reverse order. The image quality of LAFOV and SAFOV 68Ga-PSMA-11 PET was compared using subjective scoring and objective parameters. Objective parameters, including maximum and mean standardized uptake values (SUVmax and SUVmean), signal-to-noise ratio (SNR), and tumor-to-background ratio (TBR), were measured and compared.\\r\\n\\r\\nRESULTS\\r\\nLAFOV 68Ga-PSMA-11 PET exhibited superior image quality compared to SAFOV PET based on both subjective and objective parameters. LAFOV 68Ga-PSMA-11 PET had better image quality and higher lesion SUVmax, SNR, and TBR compared to SAFOV PET. In 17.65% of patients, LAFOV 68Ga-PSMA-11 PET detected additional lesions that were unidentified on SAFOV 68Ga-PSMA-11 PET. Compared to SAFOV 68Ga-PSMA-11 PET, LAFOV 68Ga-PSMA-11 PET detected additional lesions in 33.33% of patients with biochemical recurrence and 9.09% of patients with newly diagnosed prostate cancer, leading to significant changes in clinical management.\\r\\n\\r\\nCONCLUSIONS\\r\\nIn this head-to-head comparison, LAFOV 68Ga-PSMA-11 PET demonstrated superior image quality, enhanced lesion detection, and a significant impact on clinical management for both biochemical recurrence and newly diagnosed prostate cancer patients compared to SAFOV 68Ga-PSMA-11 PET. These findings suggest that LAFOV 68Ga-PSMA-11 PET may be the preferred imaging modality for comprehensive prostate cancer evaluation.\",\"PeriodicalId\":11909,\"journal\":{\"name\":\"European Journal of Nuclear Medicine and Molecular Imaging\",\"volume\":\"88 1\",\"pages\":\"\"},\"PeriodicalIF\":7.6000,\"publicationDate\":\"2025-09-27\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Journal of Nuclear Medicine and Molecular Imaging\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00259-025-07546-y\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Nuclear Medicine and Molecular Imaging","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00259-025-07546-y","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
Superiority of long axial field-of-view 68Ga-PSMA-11 PET over short axial field-of-view PET in prostate cancer: a head-to-head comparison.
BACKGROUND AND PURPOSE
Previous studies have shown that long axial field-of-view (LAFOV) 68Ga-PSMA-11 PET/CT can significantly improve the detection rate compared to short axial field-of-view (SAFOV) 68Ga-PSMA-11 PET/CT in prostate cancer. However, the diagnostic efficiency between the two scans was compared in different cohorts, not directly within the same patients. Whether LAFOV 68Ga-PSMA-11 PET could improve image quality, enhance lesion quantification, and impact patient treatment decisions in the same patients remains unclear. To address this research gap, we performed a direct comparison of LAFOV and SAFOV 68Ga-PSMA-11 PET in the same cohort of prostate cancer patients to evaluate whether LAFOV 68Ga-PSMA-11 PET could enhance lesion identification and modify clinical management compared to SAFOV 68Ga-PSMA-11 PET.
METHODS
Thirty-four patients with prostate cancer undergoing routine 68Ga-PSMA-11 PET/CT were included and underwent a same-day dual-scanning protocol. Half of the patients first underwent a clinically routine SAFOV PET scan using continuous bed motion, followed immediately by LAFOV PET (5-minute acquisition in list mode); the other half underwent scanning in the reverse order. The image quality of LAFOV and SAFOV 68Ga-PSMA-11 PET was compared using subjective scoring and objective parameters. Objective parameters, including maximum and mean standardized uptake values (SUVmax and SUVmean), signal-to-noise ratio (SNR), and tumor-to-background ratio (TBR), were measured and compared.
RESULTS
LAFOV 68Ga-PSMA-11 PET exhibited superior image quality compared to SAFOV PET based on both subjective and objective parameters. LAFOV 68Ga-PSMA-11 PET had better image quality and higher lesion SUVmax, SNR, and TBR compared to SAFOV PET. In 17.65% of patients, LAFOV 68Ga-PSMA-11 PET detected additional lesions that were unidentified on SAFOV 68Ga-PSMA-11 PET. Compared to SAFOV 68Ga-PSMA-11 PET, LAFOV 68Ga-PSMA-11 PET detected additional lesions in 33.33% of patients with biochemical recurrence and 9.09% of patients with newly diagnosed prostate cancer, leading to significant changes in clinical management.
CONCLUSIONS
In this head-to-head comparison, LAFOV 68Ga-PSMA-11 PET demonstrated superior image quality, enhanced lesion detection, and a significant impact on clinical management for both biochemical recurrence and newly diagnosed prostate cancer patients compared to SAFOV 68Ga-PSMA-11 PET. These findings suggest that LAFOV 68Ga-PSMA-11 PET may be the preferred imaging modality for comprehensive prostate cancer evaluation.
期刊介绍:
The European Journal of Nuclear Medicine and Molecular Imaging serves as a platform for the exchange of clinical and scientific information within nuclear medicine and related professions. It welcomes international submissions from professionals involved in the functional, metabolic, and molecular investigation of diseases. The journal's coverage spans physics, dosimetry, radiation biology, radiochemistry, and pharmacy, providing high-quality peer review by experts in the field. Known for highly cited and downloaded articles, it ensures global visibility for research work and is part of the EJNMMI journal family.